Vera Therapeutics (VERA) Operating Leases (2022 - 2025)

Vera Therapeutics (VERA) has 4 years of Operating Leases data on file, last reported at $1.9 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Leases fell 22.24% year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2025 stood at $1.9 million (down 22.24% YoY), and the FY2025 full-year result was $1.9 million, down 22.24% from the prior year.
• Operating Leases for Q4 2025 stood at $1.9 million, down from $2.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $5.4 million in Q1 2022 and bottomed at $455000.0 in Q2 2024.
• The 4-year median for Operating Leases is $2.4 million (2024), against an average of $2.7 million.
• The widest annual swing landed in 2024, when Operating Leases slumped 82.3%; it then surged 390.77% in 2025.
• A 4-year view of Operating Leases shows it stood at $3.8 million in 2022, then tumbled by 63.59% to $1.4 million in 2023, then jumped by 76.92% to $2.5 million in 2024, then declined by 22.24% to $1.9 million in 2025.
• The last three Operating Leases figures came in at $1.9 million (Q4 2025), $2.1 million (Q3 2025), and $2.2 million (Q2 2025), per Business Quant data.

Peer Comparison